Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Ardelyx ( (ARDX) ).
Ardelyx, Inc. has appointed Sue Hohenleitner as its new chief financial officer, effective November 4, 2025. Previously, Ms. Hohenleitner held various senior finance roles at Johnson & Johnson, including Vice President and CFO of J&J Innovative Medicine North America. Her appointment is accompanied by a comprehensive compensation package, including a base salary, bonus, stock options, and restricted stock units, reflecting Ardelyx’s strategic move to strengthen its financial leadership.
The most recent analyst rating on (ARDX) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Ardelyx stock, see the ARDX Stock Forecast page.
Spark’s Take on ARDX Stock
According to Spark, TipRanks’ AI Analyst, ARDX is a Neutral.
Ardelyx’s overall stock score is driven by its challenging financial performance, with persistent profitability issues and increased leverage. Despite strong revenue growth and positive sentiment from the earnings call, the technical indicators suggest bearish momentum. The valuation reflects the company’s focus on growth rather than profitability, typical for the biotechnology sector.
To see Spark’s full report on ARDX stock, click here.
More about Ardelyx
Average Trading Volume: 3,653,942
Technical Sentiment Signal: Sell
Current Market Cap: $1.21B
See more insights into ARDX stock on TipRanks’ Stock Analysis page.